Paramesonephric duct

Müllerian ducts (or paramesonephric ducts) are paired ducts of the embryo that run down the lateral sides of the urogenital ridge and terminate at the Müllerian eminence in the primitive urogenital sinus. In the female, they will develop to form the Fallopian tubes, uterus, cervix, and the upper two-thirds of the vagina; in the male, they are lost. These ducts are made of tissue of mesodermal origin.

Development


The female reproductive system is composed of two embryological segments: the urogenital sinus and the Müllerian ducts. The two are conjoined at the Müllerian tubercle. Müllerian ducts are present on the embryo of both sexes. Only in females do they develop into reproductive organs. They degenerate in males, but the adjoining Wolffian ducts develop into male reproductive organs. The sex based differences in the contributions of the Müllerian ducts to reproductive organs is based on the presence, and degree of presence, of Müllerian Inhibiting factor.

During the formation of the urinary system which functions in the maintaining a constant balance of water, electrolytes and other bodily fluids the müllerian ducts are formed. A new pair of müllerian (paramesonephric) ducts are formed just lateral to the mesonephric ducts in both female and male embryos during the 6th week of development of the urinary system,  during the time the germ cells are beginning to start their migration from the yolk sac and now arriving in the mesenchyme of the dorsal body wall. These ducts are formed by the craniocuadal invagination of a ribbon of thickened coelomic epithelium that extends from the third thoracic segment caudally to the posterior wall of the urogenital sinus. The caudal tips of the müllerian ducts then begin to grow in order to connect with the undeveloped pelvic urethra that can be located just medial to the openings of the right and left mesonephric ducts. The tips of the two müllerian ducts stick to each other just before they contact the undeveloped pelvic urethra. A funnel-shaped opening can be noted at the cranial ends of the müllerian ducts into the coelom.

Regulation of development
The development of the Müllerian ducts is controlled by the presence or absence of "AMH", or Anti-Müllerian hormone (also known as "MIF" for "Müllerian-inhibiting factor", or "MIH" for "Müllerian-inhibiting hormone").

Function
The müllerian ducts will give rise to the fallopian tubes, uterus and cranial portion of the vagina, while on the other hand the mesonephric ducts will degenerate. The mesonephric duct will begin to regress in females due to the absence of the male androgens. In comparison, the müllerian duct will begin to proliferate and differentiate into a cranial-caudal progression in order to form the aforementioned structures; the fallopian tube, uterus, and the upper vagina. However during this time, the single-layered müllerian duct epithelium differentiates into other structures ranging from the ciliated columnar epithelium in the fallopian tube to stratified squamous epithelium in the vagina. However in comparison to the mesonephric duct both the müllerian duct and the mesonephric duct share majority of the same menchyme due to the Hox gene expression. The genes expressed play a very critical role in the mediatin the reginal characterization of strucutes found along the cranial-caudal axis of the female reproductive tract.

Anti- Müllerian Hormone
Anti- Müllerian hormone (Amh) or Müllerian-inhibiting substance (Mis) is a glycoprotein hormone that is secreted by pre- Sertoli cells as they begin their morphologic differention in response to Sry. Amh is a known to be a member of the TgfB family and is expressed only by Sertoli cells. Amh begins to be secreted by Sertoli cells around week 8 which in turn causes the müllerian ducts to regress very rapidly between the 8th and 10th weeks. However, small müllerian ducts and still be identified, and the remnants can be detected in the adult male, including being located in the appendix testis which is a rather small cap of tissue that is associated with the testis. Remnants of the müllerian duct and also be found in the prostatic utricle which is an expansion of the prostatic urethra. In the femal embryos müllerian ducts do not regress. Amh receptor- type II (Amhr-II) also known as Misr-II will cause Amh to act indirectly on mesenchymal cells that are surrounding the müllerian duct rather than acting directly on the epithelium of the duct. This receptor activation will induce the müllerian duct to regress. The importance of mesenchyme-to-epithelial singnal continuance is to maintain the Amhr-II expression in the mesenchyme, because in the absence of the Wnta7a within the epithelium duct the Amhr-II expression will become lost and the müllerian derivatives will become retained in the males throwing off the urogenital system. Peristen müllerian duct syndrome including cryptorchidism (undescended testis) or ectopic testis with inguinal hernias have been identified in human males due to AMH and AMHR-II gene mutations. Recent studies have shown that another Amh receptor group, the Amh receptor-type I (Amhr-I) receptor group, has been noted based on the Amh being a TgfB/Bmp family member. Recent studies have shown that ALK2, Alk3 (or Bmpr 1a) and Alk6 all serve as Amhr-I receptors. When these receptors are blocked or knocked out in mice within the müllerian duct mesenchymek the Amh-induced müllerian duct regression is lost.

Mutations in AMH
Individuals that are 46, Xy and have been tested positive for mutations in their AMH or AMH receptor genes have been known to exhibit features typical of that which are exhibited in persistent müllerian duct syndrome due to the fact that the müllerian ducts fail to regress. When this happens the individuals develop structures that are derived from the müllerian duct, and also structures that are derived from the mesonephric duct. A male that has persistent müllerian duct syndrome may have a cervix, uterus and fallopian tubes as well as vas differentia along with male external genitalia. The female organs are in the correct anatomical position but the position of the testis varies. On average, 60% to 70% both testes will lie in the normal position and as for the ovaries about 20% to 30% of the time, one of the testis will lie within the inguinal hernial sac while in other cases the testes will lie within the same inguinal hernia sac. However whenever an individual exhibits persistent müllerian duct syndrome the vasa deferentia will run along the lateral sides of the uterus.

Müllerian duct anomalies
Anomalies that develop within the müllerian duct system continue to puzzle and fascinate obstetricians and gynecologist. The müllerian ducts play a critical role in the female reproductive tract and differentiate to form the fallopian tubes, uterus, superior vagina as well as the uterine cervix. Many types of disorders can occur when this system is disrupted ranging from uterine and vagina agenises to the duplication of unwanted cells of the uterus and vagina. Müllerian malformations are usually related to abnormalities of the renal and axial skeletal system. Malfunction in the ovaries and age onset abnormalaites can also be associated with most müllerian ducts. Most abnormalities are often recognized once the external genitalia is no longer masked and the internal reproductive organ abnormalities become revealed. Due to a very broad range of anomalies it is very difficult to diagnose müllerian duct anomalies.

Management
Due to improved surgical instruments and technique women with müllerian duct anomalies can have normal sexual relations. Through the use of Vecchietti and Mclndoe procedures women can carry out their sexual activity. On another note, many other surgical advances have tremendously improved fertility chances as wells as obstetric outcomes. Assisted reproductive technology makes it possible for some women that have müllerian duct anomalies to conceive and give birth to health babies.

Eponym
They are named after Johannes Peter Müller, a physiologist who described these ducts in his text "Bildungsgeschichte der Genitalien" in 1830.